Showing results (11-20 of 43) with videos related to
Sort By:
Pageof 5
Drug and Chemical Toxicology|November 26, 2010
Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in ratsNaoki Ashizawa, Takeo Shimo, Koji Matsumoto, et al.Archives of Toxicology|January 23, 2014
Xanthine crystals induced by topiroxostat, a xanthine oxidoreductase inhibitor, in rats, cause transitional cell tumorsTakeo Shimo, Mitsuyoshi Moto, Naoki Ashizawa, et al.ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering ActivityJunichiro Uda, Seiichi Kobashi, Sachiho Miyata, et al.Toxicology and Applied Pharmacology|November 7, 2006
Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitorNaoki Ashizawa, Takeo Shimo, Koji Matsumoto, et al.Toxicologic Pathology|April 2, 2009
FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeysTakeo Shimo, Naoki Ashizawa, Mitsuyoshi Moto, et al.Bioorganic & Medicinal Chemistry Letters|November 26, 2008
Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitorsTakahiro Sato, Naoki Ashizawa, Takashi Iwanaga, et al.Bioorganic & Medicinal Chemistry Letters|September 29, 2009
Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]Takahiro Sato, Naoki Ashizawa, Koji Matsumoto, et al.Journal of Bone and Mineral Metabolism|February 4, 2019
Novel bisphosphonate compound FYB-931 preferentially inhibits aortic calcification in vitamin D3-treated ratsKoichi Ishida, Naoki Ashizawa, Koji Matsumoto, et al.Nefrologia|September 27, 2022
Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplaninYing Zhang, Yoshiyasu Fukusumi, Mutsumi Kayaba, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 18, 2015
Xanthine oxidoreductase activity assay in tissues using stable isotope-labeled substrate and liquid chromatography high-resolution mass spectrometryTakayo Murase, Mai Nampei, Mitsuru Oka, et al.Pageof 5